Weiss Ratings Reiterates Sell (D-) Rating for Talphera (NASDAQ:TLPH)

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Talphera (NASDAQ:TLPH), indicating ongoing concerns about the company's stock performance.
• Talphera's stock increased 4.8% to $1.32 during mid-day trading, despite its previous underperformance, with a market capitalization of $60.18 million.
• In its last earnings report, Talphera beat analysts' expectations by reporting an EPS of ($0.10), but is projected to post a fiscal year EPS of (-0.64).

Talphera (NASDAQ:TLPH - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Talphera Stock Up 4.8%

TLPH stock traded up $0.06 during mid-day trading on Wednesday, reaching $1.32. 743,478 shares of the stock traded hands, compared to its average volume of 537,908. Talphera has a 52 week low of $0.38 and a 52 week high of $1.45. The business has a 50-day moving average of $0.70 and a two-hundred day moving average of $0.56. The firm has a market capitalization of $60.18 million, a PE ratio of -3.30 and a beta of 0.03.

Talphera (NASDAQ:TLPH - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. On average, equities research analysts anticipate that Talphera will post -0.64 EPS for the current fiscal year.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.